Scarica l'app Stockscreener
63.75
2.83%
-1.86
Precedente Chiudi:
$65.61
Aprire:
$66.57
Volume 24 ore:
628.28K
Relative Volume:
1.09
Capitalizzazione di mercato:
$3.45B
Reddito:
$155.82M
Utile/perdita netta:
$-40.42M
Rapporto P/E:
-89.79
EPS:
-0.71
Flusso di cassa netto:
$3.58M
1 W Prestazione:
-2.27%
1M Prestazione:
-4.24%
6M Prestazione:
-4.34%
1 anno Prestazione:
+6.30%
Intervallo 1D:
$63.46
$66.66
Intervallo di 1 settimana:
$62.38
$67.00
Portata 52W:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Confronta ACLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
63.75 | 3.45B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN
Arcellx (ACLX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is Arcellx (ACLX) Poised to Capture Significant Market Share? - Yahoo Finance UK
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World
(ACLX) Trading Advice - Stock Traders Daily
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Benzinga
Arcellx Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Arcellx Inc’s Anito-cel: A Promising Investment with Innovative Therapeutics and Market Potential - TipRanks
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Financial Snapshot: Analyzing Arcellx Inc (ACLX)’s Key Ratio Metrics - The Dwinnex
Arcellx (NASDAQ:ACLX) Shares Down 5.4%What's Next? - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 6.6% - MarketBeat
Taking a Closer Look At Arcellx Inc (ACLX) Following Its Recent Trade - Knox Daily
arcellx director kavita patel sells $96,854 in stock - MSN
Financial Review: Arcellx (NASDAQ:ACLX) versus C4 Therapeutics (NASDAQ:CCCC) - Defense World
arcellx director kavita patel sells $96,854 in stock By Investing.com - Investing.com Australia
(ACLX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - MarketBeat
Moody Aldrich Partners LLC Sells 16,122 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Analysts Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - Defense World
Vanguard Group Inc's Strategic Acquisition of Arcellx Inc Shares - GuruFocus.com
Stifel maintains Buy on Arcellx shares, target at $122 - MSN
Stifel maintains Buy on Arcellx shares, target at $122 By Investing.com - Investing.com Australia
(ACLX) On The My Stocks Page - Stock Traders Daily
Cantor Fitzgerald Estimates Arcellx FY2025 Earnings - Defense World
Brokers Issue Forecasts for Arcellx FY2025 Earnings - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcellx Inc Azioni (ACLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Elghandour Rami | SEE REMARKS |
Feb 07 '25 |
Option Exercise |
0.00 |
70,211 |
0 |
187,486 |
| Patel Kavita | Director |
Feb 04 '25 |
Option Exercise |
6.66 |
1,500 |
9,990 |
1,500 |
| Patel Kavita | Director |
Feb 04 '25 |
Sale |
64.57 |
1,500 |
96,855 |
0 |
| Patel Kavita | Director |
Jan 14 '25 |
Option Exercise |
6.66 |
1,500 |
9,990 |
1,500 |
| Patel Kavita | Director |
Jan 14 '25 |
Sale |
65.87 |
1,500 |
98,801 |
0 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 03 '25 |
Option Exercise |
0.00 |
16,519 |
0 |
38,818 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 07 '25 |
Sale |
75.53 |
4,230 |
319,485 |
28,638 |
| Heery Christopher | CHIEF MEDICAL OFFICER |
Jan 08 '25 |
Sale |
73.69 |
3,553 |
261,831 |
25,085 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 03 '25 |
Option Exercise |
0.00 |
15,339 |
0 |
38,834 |
| Gilson Michelle | CHIEF FINANCIAL OFFICER |
Jan 07 '25 |
Sale |
75.68 |
14,012 |
1,060,474 |
13,579 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):